Cooper Pharma Limited - Due diligence report

A 360° intelligence report on Cooper Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …

1989-02-02 Delhi, Delhi Active Unlisted Active Compliant
Share
View plans
CP Cooper Pharma Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Cooper Pharma — 360° Intelligence Report

Generated from MCA filings & public records
90/100
Trust Score
Low Risk

Cooper Pharma is assessed as Low Risk with a Trust Score of 90/100. Cooper Pharma is an active public limited indian non-government company incorporated in 1989, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 29 Jun 2026 from the latest processed filings. Cooper Pharma Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
90/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
85/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open (3.03 cr) · 4 satisfied (22.60 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others2 48.0 cr
Punjab National Bank2 48.0 cr
Dbs Bank Ltd.1 48.0 cr
Small Industries Developmnt Bank Of India1 48.0 cr
Compliance Score: 85/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (229 disclosure(s)).
Legal cases on record (1)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
RAKESH BHARGAVA 01234567 Director 01/04/2018 6 yrs Approved
Dinesh Kumar 01234567 Director 01/04/2018 6 yrs Approved
ABHISHEK BHARGAVA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Adrene Prime Private Limited Associate Company 74.00%

Key managerial personnel: RAKESH BHARGAVA (Managing Director) · ABHISHEK BHARGAVA (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
Net margin improved to 38%.
EPFO headcount growing - hiring signal.
Operating for 37+ years.
Active EPFO - real payroll on record.
Distress signals & risk flags
2 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.46 cr.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment92/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 3.03 cr already registered.
  • Compliance record supports lending.
Investor view94/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 6 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
15 Sep 2025
Charge satisfied
Others
02 Apr 2025
Charge created
Others - 12.50 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
11 Mar 2025
Charge satisfied
Others
29 Sep 2024
Director ceased
Dinesh Kumar
05 Jun 2024
Director appointed
Dinesh Kumar (Director)
11 Jan 2022
Charge satisfied
Dbs Bank Ltd.
28 Jul 2021
Charge satisfied
Punjab National Bank
29 Oct 2020
Director ceased
RAVI KANT
17 Dec 2019
Director ceased
NAGENDRA PRASAD BRAMHADEV UPADHYAY
21 May 2019
Director ceased
ABHIJIT SENGUPTA
Director ceased
ASHOK KUMAR PANDEY
Director ceased
MHD BASSAM NAASSAN
01 Jan 2019
Director ceased
ABHISHEK BHARGAVA
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Meridian Enterprises U21003MH1990PTC055663 Mumbai, Maharashtra, India
Choksi Organics Private Limited U24231GJ2000PTC038329 Ahmedabad, Gujarat, India
Althea Pharma Private Limited U24232GJ2004PTC044200 Vapi, Gujarat, India
Sohan Industries Private Limited U24290MH1995PTC087260 Thane, Maharashtra, India
Steris Healthcare Private Limited U74999RJ2018PTC061186 Jaipur, Rajasthan, India
Nishant Aromas U74999MH2019PTC326261 Mumbai, Maharashtra, India
Celebrity Biopharma Limited U24230HP2005PLC028852 Himachal Pradesh, Himachal Pradesh, India
Ronak Healthcare Private Limited U24100GJ2010PTC060001 Baroda, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Cooper Pharma before audits and certifications: compliance score 85/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Cooper Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Cooper Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 90/100, distress signals and MSME payment-delay disclosures - know whether Cooper Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Cooper Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Cooper Pharma an active company?

Cooper Pharma has MCA status “Active” with a compliance score of 85/100 (Low Risk).

Is Cooper Pharma financially healthy?

Cooper Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Cooper Pharma?

Its overall Trust Score is 90/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Cooper Pharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Cooper Pharma have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.

Is Cooper Pharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 85/100 (Low Risk).

Is it risky to lend to Cooper Pharma?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.